Objective: To characterize the effects of cerebrovascular (CV) risk factors on preclinical memory decline in cognitively normal individuals at 3 levels of genetic risk for Alzheimer disease (AD) based on APOE genotype.
prevent AD. Combined treatment of multiple CV risk factors can slow the progression of MRI lesions, 16 but cognitive outcomes have shown mixed results. 17, 18 APOE 4 is a proven genetic risk factor for AD 19 and memory declines more quickly in APOE 4 carriers than noncarriers beginning around age 55-60 years as a preclinical harbinger of impending mild cognitive impairment (MCI) and dementia. 20 CV risk factors further influence the effect of APOE 4 carrier status on cognitive decline in elderly individuals, 21 but their interaction with APOE 4 gene dose might underlie inconsistent therapeutic outcomes. There is now good evidence that AD has an extended preclinical phase, so the interactions of APOE genotype and CV risk factors in younger individuals warrant further exploration to better understand potential treatment opportunities for the prevention or delay of AD onset.
We therefore sought to characterize the effects of any of 4 major CV risk factors (CVany) including HTN, DM, CHOL, and CIG on preclinical memory decline (an established sensitive marker of AD onset) in a longitudinal cohort of APOE 4 homozygotes (HMZ), heterozygotes (HTZ), and noncarriers, as well as explore the effects of each risk factor individually.
METHODS Study participants. From January 1, 1994, through August 6, 2007 , cognitively normal residents of Maricopa County age 21 years and older were recruited through local media advertisements and underwent APOE genotyping and longitudinal neuropsychological assessment. 20 Demographic, family, and medical history data were obtained on each individual undergoing APOE genotyping, and identity was coded by a study assistant. Ancestral origin was self-reported. Genetic determination of APOE allelic status was performed using a PCRbased assay.
All identified 4 HMZ were matched by age, gender, and education to one 3/4 HTZ and 2 noncarriers. We identified more HTZ and noncarriers than HMZ (especially those persons over age 70 years, reflecting the greater number of 4 HMZ developing MCI and AD by this age), who were also eligible for enrollment. Each participant had screening tests to establish their neuropsychiatrically normal state including a neurologic examination, the Folstein Mini-Mental State Examination (MMSE), the Hamilton Depression (Ham-D) Rating Scale, the Functional Activities Questionnaire (FAQ), Instrumental Activities of Daily Living (IADL), and Structured Psychiatric Interview for DSM-III-R. We excluded anyone with potentially confounding medical, neurologic, or psychiatric problems (including a history of stroke). None met the published criteria for MCI, 22 AD, 23 other forms of dementia, or major depressive dis-order. 24 Entry criteria for all participants included a score of at least 27 on the MMSE (and scoring at least 1 out of 3 on the recall subtest), a score of 10 or less on the Ham-D rating scale at the time of their first visit, and no indication of loss of function on the FAQ and IADL.
We also excluded from the analysis anyone who subsequently met published criteria for MCI, AD, or any other form of dementia during follow-up, and thus excluded 16 participants (4 noncarriers, 4 heterozygous persons, and 8 homozygous persons). Diagnostic status at entry and follow-up was determined by a consensus panel of behavioral neurologists (R.J.C., M.N.S., G.L.A., S.Z.R., J.S., and B.K.W.). The resulting study population was identical to that previously reported 20 save for the omission of 8 individuals in whom CV risk data were missing.
Standard protocol approval and patient consent. All individuals gave their written, informed consent to participate in the study and have the results of the APOE test withheld from them, approved by the Institutional Review Boards of all participating institutions.
Memory testing. The Auditory Verbal Learning Test (AVLT)
was repeated every 1 to 2 years as part of a standardized battery of neuropsychological tests. We found the long-term memory score (LTM) of the AVLT 25 to be a sensitive marker of preclinical cognitive decline in APOE 4 carriers, 20 so LTM was again used as the primary endpoint in this study.
Cerebrovascular risk factors. CHOL, CIG, DM, and HTN were the 4 considered CV risk factor categories. CVany refers to the presence of any one or more of these 4 categories. Diagnosis made by their primary physician was supported by published guidelines for existing treatment (CHOL, DM, and HTN), 26 -28 physical examination (blood pressure, height, and weight), and serum total cholesterol measurements (available in 172 members of the APOE cohort). CIG was considered present if greater than 1 pack-year of lifetime cigarette use was endorsed. (Because there is no objective cutoff for a positive smoking history, we chose to err on the more conservative side, realizing that inclusion of individuals with limited smoking exposure could weaken our ability to find a significant effect.) CVany, CHOL, CIG, DM, and HTN were each dichotomized as present or absent regardless of treatment. CHOL, DM, HTN, and CIG were recorded at each epoch and if present at any study epoch, were treated as present even if not endorsed at each epoch. (Most individuals reported the risk factor at entry. Those diagnosed at later epochs either did not have the risk factor at entry [incident cases] or else had it but were not yet diagnosed. Given the chronicity of these risk factors relative to the study's duration, we assumed the latter as more biologically plausible.)
Longitudinal growth modeling. The longitudinal growth model we have previously used 20 was modified to incorporate individual binary cardiovascular risk factors. The original mixed model approach isolated the longitudinal effect of age on the AVLT in a cross-sectional and longitudinal sample. 29, 30 The modified model employed here allows for comparison of the predicted annual change in AVLT within noncarriers between subjects with and without a given risk factor; the same comparison within carriers; and a comparison of the effect of the risk factor between noncarriers and carriers.
The model for Y ij (the jth response for the ith individual) is as follows:
where Carrier i is the carrier status for the ith individual (1 ϭ carrier; 0 ϭ noncarrier), RiskFactor i is the presence of a given risk factor for the ith individual (1 ϭ risk factor reported at any time point; 0 ϭ risk factor not reported at any time point), Agec ij is the age Ϫ 60 (i.e., centered age) of the ith individual at the time of the jth response, and b 1i is an individual specific random effect allowing each subject to have a different intercept. Age is centered to reduce the correlation between the age and age-squared terms. From this, the longitudinal models for noncarriers without and with a given risk factor are given by:
2 ) and the longitudinal models for carriers without and with a given risk factor are given by:
We previously reported on the difference between carriers and noncarriers in the quadratic longitudinal effect of aging on AVLT 20 and thus focus this analysis on the difference between subjects with and without individual cardiovascular risk factors and whether this difference varies between carriers and noncarriers. From these longitudinal models, the estimate of ␤ 13 with confidence interval (CI) was used to assess the difference in predicted annual change in AVLT between subjects with and without a given risk factor within noncarriers, and the estimate of ␤ 13 ϩ ␤ 14 with CI was used to assess the difference in predicted annual change in AVLT between subjects with and without a given risk factor within carriers. A test of significance of ␤ 14 was used to assess whether the impact of the given risk factor differed between carriers and noncarriers. Modeling was carried out using SAS PROC MIXED (SAS version 9).
In exploratory analyses, the model was modified to replace the RiskFactor i variable with a continuous variable equal to the number of risk factors (ranging from 0 to 4) present in the subject used to test for linear trend associated with riskdose. In an additional analysis of CVany, the Carrier i variable was replaced with 2 indicator variables to assess differences between noncarriers and HTZ and between noncarriers and HMZ. Baseline characteristics and those recorded during follow-up were compared among groups by using the 2-sample t test or Pearson 2 test.
RESULTS
A total of 74 4 HMZ, 239 HTZ, and 494 4 noncarriers were included. A total of 58.1% of the cohort members had at least one CV risk factor (CVany) that did not differ between genetic subgroups ( p ϭ 0.27). APOE 4 HMZ were generally younger (mean age 56.1 Ϯ 9.3 years) with a greater frequency of first-degree relatives with dementia and had slightly longer follow-up than the other genetic subgroups, but did not appear less healthy overall ( Table 2 shows the distribution of the number of CV risk factor categories (ranging from 0 to 4). Overall, 41.9% had none, 25.3% had 1, 20% had 2, 11% had 3, and 1.8% had 4. This distribution did not differ significantly between 4 carriers and noncarriers ( p ϭ 0.10), but noncarriers had a greater proportion of individuals with 2 or more risk factors than carriers (36.3% vs 27.3%, p ϭ 0.03). In all models, APOE 4 had a significant longitudinal quadratic effect on AVLT LTM, as previously reported. 30 CVany was associated with additional longitudinal AVLT LTM decline in APOE 4 carriers (95% CI Ϫ0.195 to Ϫ0.018, p ϭ 0.02), but the effect in noncarriers was not statistically significant. When 4 HTZ and HMZ were classified as distinct groups, there was a striking effect found in HMZ (difference in predicted annual decline in LTM between subjects with and without CVany of 0.28 points, p Ͻ 0.001) but not in HTZ (difference in predicted annual decline in LTM between subjects with and without CVany annual decline in LTM of 0.012 points, p ϭ 0.82) or noncarriers (difference in predicted annual decline in LTM between subjects with and without CVany of 0.000 points, p ϭ 0.99) ( figure) .
When each risk factor was considered separately, but without controlling for the presence of the remaining risk factors, there were significant effects of CIG (95% CI Ϫ0.301 to Ϫ0.074, p ϭ 0.001), DM (95% CI Ϫ0.391 to Ϫ0.020, p ϭ 0.03), and HTN (95% CI Ϫ0.184 to Ϫ0.001, p ϭ 0.05) in 4 carriers only (table 3 and table e-1 on the Neurology ® Web site at www.neurology.org). There were insufficient numbers of HMZ with each risk factor to assess individual effects in this subgroup (table e-2). When APOE 4 carriers and noncarriers were combined, there were significant interactions with APOE 4 for CIG ( p ϭ 0.007), and trends for CHOL ( p ϭ 0.03) and DM ( p ϭ 0.06) and CVany ( p ϭ 0.08; table 3) when applying a multiple testing correction for 5 interaction tests. For the entire cohort of carriers and noncarriers, the greater the number of CV risk factor categories, the greater was the deleterious impact on AVLT LTM decline (linear trend, p ϭ 0.01). Finally, adjusting for family history as well as using continuous systolic and diastolic blood pressure and lipid measures did not alter any of the results. DISCUSSION CV risk factors were associated with greater longitudinal memory decline in preclinical APOE 4 carriers, especially in HMZ who are at the highest risk for AD, while the effect appeared limited in 4 noncarriers. Further, the greater the number of CV risk factor categories, the greater the effect on memory decline. This relatively selective effect on 4 carriers echoes the differentially worse outcomes previously reported to result from head trauma, 31 stroke, 32 carotid endarterectomy, 33 subarachnoid and intracerebral hemorrhage, 34 and carbon monoxide poisoning. 35 The causes for these effects remain speculative, but collectively suggest that APOE 4 carriers are more vulnerable to a variety of pathophysiologic insults.
Despite individual differences, all CV risk factors share important downstream pathogenic effects including endothelial dysfunction, the promotion of atherosclerosis, and stroke 36 that frequently impairs cognition. Atherosclerosis-mediated cerebral hypoperfusion in the absence of frank infarction accounts for much of the lesion burden observed on the MRI scans of aging individuals, 37 and is increased in the setting of CV risk factors. 38 Clinical effects vary and led to past controversy, but most now agree that increasing lesion burden generally correlates with declining cognitive skills (especially in the executive domain) contributing to vascular cognitive impairment and frank dementia. 39 However, although AD and vascular pathology frequently co-occur, 40 the role of CV risk factors in the cause and progression of AD itself has not been established. Memory performance differences between APOE 4 carriers with and without CV risk factors were clinically modest, but evident in HMZ even before age 60 years. Repeated test administration normally results in improved performance over time, but even in the youngest age ranges of our study, no such testretest benefit was observed in the 4 HMZ with CV risk factors (figure). APOE 4 HMZ comprise roughly 2% of the US population, and many have CV risk factors. Though they are only a subset of all those at risk, they are a particularly vulnerable group due to their very high rate of AD conversion and the younger age at which AD onset occurs. 19 Early and aggressive intervention for CV risk factors in this select group might realistically offer the chance to shift their memory trajectory to at least the level of 4 HMZ without CV risk factors, and thereby delay the decline that occurs with increasing age possibly delaying the onset of symptomatic memory loss.
There are several limitations that must be considered in the interpretation of our findings. First, while CV risk factors have been shown to correlate more strongly with measures of executive function, 40 we instead chose to specifically focus on memory. This was done because of the sensitivity of the AVLT-LTM to preclinical decline previously demonstrated in APOE 4 carriers. 20 Because we did not observe a similar difference in age-related performance between 4 carriers and noncarriers on an executive measure, the Controlled Oral Word Association Test, we chose instead to use the AVLT as a sensitive discriminator of ADmediated preclinical decline. We cannot exclude the possibility that other executive measures might show a different pattern of change, or that CV risk factors might affect executive measures differently than memory. Nonetheless, we have no reason to believe that executive measures would be more sensitive in-dicators of preclinical AD, and so were less relevant for the aims of this study.
Because we relied upon existing diagnoses, we may have underestimated the number of individuals with more subtle degrees of CV risk, and this could have reduced our power to detect an effect of CV risk on LTM. However, the overall percentages of affected individuals in our cohort were similar to those reported in population-based studies (cited in 26 -28 ) and there is no reason to believe it would selectively affect noncarriers to account for the differences we observed between groups. Also, the sample size of this study likely limited our ability to detect small effects. These 2 limitations may have contributed to the lack of statistically significant effects in the noncarrier and HTZ groups and the results for these groups should not therefore be interpreted that CV risk factors do not influence memory but rather that the effect was not detectable within the study's limitations.
We were unable to address treatment of CV risk factors since essentially all individuals were receiving treatment, and were unable to isolate each individual CV risk factor as this would have required a much larger number of participants thus limiting our main findings to CVany and the "dose" effect of multiple risk factor categories rather than continuous dose effects. Our study cohort is designed to be genetically enriched for APOE 4 rather than a random community sample. Our approach capitalizes upon this known genetic risk factor, has proven sensitivity to age-related memory decline, 20 and despite the many advantages of community sampling, allowed us to avoid its potential pitfalls of including unhealthy individuals, inadequate or incomplete testing, and inadequate numbers of 4 HMZ, the subgroup in which we found the strongest effects.
With these limitations in mind, we found that CV risk factors had a deleterious effect on age-related memory decline in APOE 4 HMZ evident even in Abbreviations: CHOL ϭ hypercholesterolemia; CIG ϭ cigarette smoking; CV ϭ cerebrovascular; CVany ϭ any of 4 cerebrovascular risk factors; DM ϭ diabetes mellitus; HTN ϭ hypertension. a Difference between subjects with and without the given CV risk factor. Negative values indicate larger predicted annual decline in subjects with the given CV risk factor relative to subjects without the given CV risk factor. b Remained statistically significant when applying Hochberg step-up method to adjust for the 5 statistical tests of interaction.
the youngest members of our cohort, and the greater the number of CV risk factors, the greater the deleterious effect. Our findings support the general rationale that CV risk factors are therapeutically modifiable targets that contribute to memory decline in those at greatest risk for AD.
